A Study to Evaluate the Accuracy of a Subset of the Length-109 Probe Set Panel (a Genetic Test) in Predicting Response to Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis
- First Posted Date
- 2013-11-20
- Last Posted Date
- 2017-01-05
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 103
- Registration Number
- NCT01988961
An Efficacy and Safety Study of Daratumumab in Patients With Multiple Myeloma Who Have Received at Least 3 Prior Lines of Therapy (Including a Proteasome Inhibitor [PI] and Immunomodulatory Drug [IMiD]) or Are Double Refractory to a PI and an IMiD
- First Posted Date
- 2013-11-15
- Last Posted Date
- 2018-06-25
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 124
- Registration Number
- NCT01985126
A Study to Assess the Pharmacokinetics of Intranasally Administered Esketamine in Healthy Japanese and Caucasian Volunteers
- First Posted Date
- 2013-11-08
- Last Posted Date
- 2014-01-28
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 29
- Registration Number
- NCT01980303
A Study to Evaluate the Effects of JNJ-54861911 on Amyloid Beta Processing in Cerebrospinal Fluid and Plasma in Patients With Prodromal Alzheimer's Disease
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2013-11-07
- Last Posted Date
- 2015-06-25
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 45
- Registration Number
- NCT01978548
A Study of PCI-32765 (Ibrutinib) in Combination With Either Bendamustine and Rituximab or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Participants With Previously Treated Indolent Non-Hodgkin Lymphoma
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2013-11-01
- Last Posted Date
- 2024-08-09
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 403
- Registration Number
- NCT01974440
A Study of PCI-32765 (Ibrutinib) Versus Rituximab in Relapsed or Refractory Chronic Leukemia/Lymphoma
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2013-10-31
- Last Posted Date
- 2018-07-24
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 160
- Registration Number
- NCT01973387
A Study to Investigate the Absorption, Metabolism, and Excretion of JNJ-38518168 After a Single Oral Dose in Healthy Male Participants.
- First Posted Date
- 2013-10-25
- Last Posted Date
- 2013-10-25
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 6
- Registration Number
- NCT01970020
A Pharmacokinetic Study in Healthy Participants to Assess the Pharmacokinetics and Safety of a Supratherapeutic Dose of PCI-32765 (Ibrutinib) Capsule and Solution Formulations Administered With Food
Phase 1
Completed
- Conditions
- First Posted Date
- 2013-10-25
- Last Posted Date
- 2014-02-13
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 8
- Registration Number
- NCT01969266
A Study to Evaluate the Effectiveness and Safety of CNTO6785 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2013-10-21
- Last Posted Date
- 2016-06-08
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 187
- Registration Number
- NCT01966549
A Phase II Open Label Study of Xilonix in Subjects With Pyoderma Gangrenosum
- First Posted Date
- 2013-10-18
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 10
- Registration Number
- NCT01965613
- Locations
- 🇺🇸
XBiotech Investigative Site, Tallahassee, Florida, United States
© Copyright 2024. All Rights Reserved by MedPath